{
    "nct_id": "NCT03701581",
    "official_title": "4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy",
    "inclusion_criteria": "Inclusion Criteria\n\n* Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c), planning to undergo Robotic-Assisted Laparoscopic Bilateral Nerve Sparing Radical Prostatectomy (NSRP)\n* Prostate-Specific Antigen (PSA) levels less than 15 ng/ml (within the last 12 months), with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g. radiation or androgen deprivation therapy) is not expected to be needed\n* Ages 45-75\n* An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score of greater than or equal to 17 at time of screening\n* Has experienced at least 6 months of regular sexual activity and sexual activity during the 12 weeks prior to prostate biopsy or surgery\n* Willingness to abstain from treatments for Erectile Dysfunction until 3 months after surgery\n* Willingness to participate and able to provide informed consent\n\nExclusion Criteria\n\n* Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate cancer (stage T3 or greater), positive lymph nodes or positive surgical margins\n* Neo-adjuvant therapy prior to NSRP\n* History of recurrent prostate cancer\n* History of seizures, multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of non-organ confined or metastatic prostate cancer (clinical Stages T3 or greater)\n* History of known hypersensitivity to 4AP\n* Patients with history of penile surgery other than circumcision or endoscopic urethral stricture surgery\n* Renal impairment based on calculated GFR (GFR<60 mL/min)\n* Use of any other aminopyridine medications for any other indication\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 45 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}